SABS

Healthcare Biotechnology

SAB Biotherapeutics, Inc.

$2.98

-0.17 -5.40% today

Price History

Not enough data

Key Stats

Market Cap

271.14M

Avg Volume

491,603

P/E (TTM)

12.42

EPS

$0.24

52W High

$5.15

52W Low

$2.06

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-3.12

P/B Ratio

1.16

EV/EBITDA

-2.53

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(11.3%)

Return on Assets

(33.5%)

Liquidity & Leverage

Current Ratio

9.22

Quick Ratio

8.93

Debt / Equity

0.02

Total Cash

102.63M

Total Debt

5.13M

About

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.